Search results for ""Author William Lazonick""
Edward Elgar Publishing Ltd Organization and Technology in Capitalist
Book SynopsisFor more than 20 years, William Lazonick has been one of the world's leading analysts of the dynamics of industrial development and change in international economic leadership. This impressive volume presents a coherent selection of Professor Lazonick's most important work on industrial development in Britain and the United States.The first part of the book contains articles on the decline of the British economy, including a recent summary of the debates on the British cotton textile industry and international competition. The second part focuses on labour, management and technology in the rise and recent decline of the US economy, and includes an up-to-date summary essay on organizational capabilities in American industry. Professor Lazonick's essays make historical analysis relevant to the present and put economic analysis back in touch with evolving reality. This approach, together with his unique combination of historical, statistical and theoretical methodologies, will ensure that this volume proves invaluable to economists and historians alike.Trade Review'This is a timely useful collection of Professor Lazonick's principal articles on those related themes in economic history to which he has devoted his considerable scholarly abilities and his stimulating search for originality.'
£116.00
Edward Elgar Publishing Ltd ORGANIZATIONAL CAPABILITY AND COMPETITIVE
Book SynopsisIn an age of intense international competition, enterprises, regions and nations depend on their organizational capabilities to gain competitive advantage in global markets.This volume brings together critical scholarly contributions to historical and contemporary debates over the origins and characteristics of organizational capabilities that result in competitive advantage. Included are case studies drawn from textiles, chemicals, automobiles, computers and agriculture that illustrate how organizational capabilities generate sustained competitive success. In a new introduction, the editors, who have themselves been in the forefront of analysing the dynamics of innovation and industrial development, provide a state-of-the-art survey of the subject.Table of ContentsHistorical debates: contemporary debates: the dynamics of success: policy perspectives.
£285.00
Cambridge University Press From Financialisation to Innovation in UK Big
Book SynopsisThis Element analyses the tension between innovation and financialisation in the UK pharmaceutical industry, focusing on AstraZeneca and GlaxoSmithKline. This title is also available as Open Access on Cambridge Core.Trade Review'Governments around the world are rediscovering the importance of industrial policy for productive investments and innovation, especially in sectors that are strategic in dealing with todays' multiple environmental and health crises. Such efforts are however pointless if firms are allowed to financialise and extract value from productive organisations. Through a meticulous historical analysis of two major pharmaceutical companies, this extraordinary book shows the dangers of financialisation and how we can control it. It is a tremendously important and timely book for economists, policy-makers, and citizens looking to promote sustainable prosperity for the many.' Ha-Joon Chang, Professor of Economics, SOAS University of London'In this impressive book, the authors establish a clear link between the innovation performance of companies and their governance. They do this by looking at the innovation performance of two leading UK pharmaceutical companies, AstraZeneca and GlaxoSmithKline, in the ten years after the mergers in 1999 and 2000 which created them. During the period both companies adopted US-style governance models which linked the reward of executives to increases in the share price of their companies. At the same time executives were allowed to raise the share price of their companies by share buybacks … By establishing such a clear link between the innovation performance of companies and their governance, this book makes an important contribution to the study of how the innovation performance of companies can be improved, and it should be read by both executives and Government policymakers.' Lord David Sainsbury, Chancellor of the University of Cambridge and Former UK Under-Secretary of State for Science and Innovation'This fascinating book adeptly raises the alarm about how financialisation has impacted and continues to impact innovation and selection of R&D pipelines in the pharmaceutical sector. Tracing the experiences of two of the largest global pharmaceutical companies, the authors unpack how financialization helps firms mete out rewards to senior executives beyond those justified by any value creation metrics. An important contribution to the literature and essential reading for anyone who wants to understand the workings of the sector.' Padmashree Gehl Sampath, Director, Global Access in Action, Harvard University'The tension between financialization (and the associated incentives for share buybacks and focus on shareholder value alone) and the needs of productive investment and innovation has become a defining feature of contemporary capitalism-nowhere more evident than in the pharma industry. This detailed study of two UK firms shows that different, more socially desirable outcomes are possible: appropriate regulatory and policy regimes can support collective innovation efforts to create value for society rather than just for shareholders. This critically important book is essential reading for anyone concerned with viable corporate governance models that are alternatives to destructive forms of financialized capitalism.' Jayati Ghosh, Professor of Economics, University of Massachusetts Amherst'What's the true mission of a large pharmaceutical firm today? Are you part of those who doubt about where their key priorities lie? This book is a must-read, enlightening and solid piece of research for anyone who cares about innovation-led economic growth. These distinguished authors gracefully execute a rigorous stepwise demonstration of why brilliant leading pharmaceutical firms in the United Kingdom and the United States of America fail to deliver innovation-led value. The good news is that the book also shows how they can move away from deleterious modes of financialization and engage in value creating organizational learning.' Pascale Lehoux, Professor, Department of Health Management, Evaluation and Policy, Université de Montréal'The authors give us an exciting, solidly based exploration of the shifting links between financialization and new drug development at two leading British pharmaceutical giants, AstraZeneca and GlaxoSmithKline. As Covid has made clear, we all have a stake in this history.' Louis Galambos, Research Professor, History, Johns Hopkins UniversityTable of Contents1. Introduction; 2. Innovation and Competition in the Global Pharmaceutical Industry; 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry; 4. AstraZeneca; 5. GlaxoSmithKline; 6. Explaining the Financialisation-to-Innovation Transition at AstraZeneca and GlaxoSmithKline; Appendix; References.
£16.15
